Lux Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.luxbio.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01243983
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00851734
- Locations
- 🇺🇸
Product Investigations, Conshohocken, Pennsylvania, United States
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
- Conditions
- Corneal TransplantationCorneal Graft Rejection
- Interventions
- Other: Placebo
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00447642
- Locations
- 🇺🇸
Cornea Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸USC Doheny Eye Institute, Los Angeles, California, United States
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT00447187
- Locations
- 🇺🇸
Cornea Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸USC Doheny Eye Institute, Los Angeles, California, United States
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
- Conditions
- Uveitis, PosteriorUveitis, IntermediatePanuveitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT00404612
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸University of Illinois - Chicago, Chicago, Illinois, United States
- Prev
- 1
- 2
- Next